Guhlmann A, Keppler A, Kästner S, Krieter H, Brückner U B, Messmer K, Keppler D
Division of Tumor Biochemistry, Deutsches Krebsforschungszentrum, Heidelberg, Federal Republic of Germany.
J Exp Med. 1989 Dec 1;170(6):1905-18. doi: 10.1084/jem.170.6.1905.
Leukotriene C4 (LTC4) underwent rapid elimination from the circulating blood and was extensively converted to LTD4 within the vascular space of the guinea pig. To mimic the elimination and metabolism of endogenous LTC4 generated during anaphylaxis, 14,15-3H-labeled LTC4 was infused intravenously over a period of 15 min, leading to a recovery in bile of 85% of the infused LT radioactivity within 2 h. Corresponding to the tracer studies, LTD4 and, to a lesser extent, LTC4 were the predominant endogenous cysteinyl LTs in guinea pig bile. The biliary production rate of endogenous LTD4 increased from 0.3 +/- 0.1 to 6.2 +/- 1.8 pmol x min-1 x kg-1 (p less than 0.001) during anaphylactic shock induced by intravenous injection of OVA (0.2 mg/kg) into sensitized guinea pigs. A novel LT biosynthesis inhibitor (MK-886; 10 mg/kg, i.v., 15 min before antigen challenge) suppressed the antigen-induced cysteinyl LT production by greater than 92% (p less than 0.001). This inhibition of systemic LTC4 formation was associated with a complete protection against lethal anaphylactic shock in animals pretreated in addition with the H1 receptor antagonist pyrilamine. Pretreatment with either the inhibitor of LT synthesis or the histamine receptor antagonist reduced the lethality during anaphylactic shock from 100 to 60 and 78%, respectively. In artificially ventilated, pyrilamine-pretreated animals, the antigen-induced decrease in dynamic lung compliance and the rise in hematocrit were significantly reduced (p less than 0.05) by pretreatment with the inhibitor of LT synthesis. Dexamethasone at high doses (10 mg/kg, i.p., once daily for 7 d, or in a single dose of 10 mg/kg, i.v., 3.5 h before challenge) had no inhibitory effect on LT generation during anaphylaxis in vivo. However, in resident peritoneal macrophages, harvested from these dexamethasone-treated sensitized guinea pigs and stimulated with zymosan, both cysteinyl LT and 6-keto-PGF1 alpha formation were strongly suppressed. These studies indicate an important role of cysteinyl LTs in systemic anaphylaxis in vivo and demonstrate the blockade of anaphylactic LT generation by a novel inhibitor of LT biosynthesis (MK-886) but not by dexamethasone.
白三烯C4(LTC4)在循环血液中迅速清除,并在豚鼠血管腔内广泛转化为LTD4。为模拟过敏反应期间内源性LTC4的清除和代谢,将14,15-3H标记的LTC4在15分钟内静脉输注,结果在2小时内胆汁中回收了85%的输注LT放射性。与示踪研究一致,LTD4以及程度较轻的LTC4是豚鼠胆汁中主要的内源性半胱氨酰白三烯。在致敏豚鼠静脉注射OVA(0.2mg/kg)诱导的过敏性休克期间,内源性LTD4的胆汁生成率从0.3±0.1增加到6.2±1.8pmol·min-1·kg-1(p<0.001)。一种新型白三烯生物合成抑制剂(MK-886;10mg/kg,静脉注射,在抗原攻击前15分钟)抑制抗原诱导的半胱氨酰白三烯生成超过92%(p<0.001)。这种对全身LTC4形成的抑制与对预先用H1受体拮抗剂吡苄明处理的动物致命性过敏性休克的完全保护相关。用白三烯合成抑制剂或组胺受体拮抗剂预处理分别将过敏性休克期间的致死率从100%降低到60%和78%。在人工通气、预先用吡苄明处理的动物中,用白三烯合成抑制剂预处理可显著降低抗原诱导的动态肺顺应性降低和血细胞比容升高(p<0.05)。高剂量地塞米松(10mg/kg,腹腔注射,每日一次,共7天,或单次剂量10mg/kg,静脉注射,在攻击前3.5小时)对体内过敏反应期间的白三烯生成没有抑制作用。然而,从这些用地塞米松处理的致敏豚鼠收获并用酵母聚糖刺激的驻留腹膜巨噬细胞中,半胱氨酰白三烯和6-酮-PGF1α的形成均受到强烈抑制。这些研究表明半胱氨酰白三烯在体内全身过敏反应中的重要作用,并证明一种新型白三烯生物合成抑制剂(MK-886)可阻断过敏性白三烯生成,而地塞米松则不能。